Mark Ragosa - 06 Dec 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
06 Dec 2024
Net transactions value
-$358,763
Form type
4
Filing time
10 Dec 2024, 16:34:26 UTC
Previous filing
05 Dec 2024
Next filing
14 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise $25,889 +2,406 +10% $10.76 25,364 06 Dec 2024 Direct F1
transaction KNSA Class A Ordinary Share Sale $190,771 -8,969 -28% $21.27 22,958 06 Dec 2024 Direct F1, F2
transaction KNSA Class A Ordinary Share Options Exercise $209,346 +18,860 +82% $11.10 41,818 09 Dec 2024 Direct F1
transaction KNSA Class A Ordinary Share Sale $403,227 -18,860 -45% $21.38 22,958 09 Dec 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -2,406 -8.9% $0.000000 24,528 06 Dec 2024 Class A Ordinary Share 2,406 $10.76 Direct F1, F4
transaction KNSA Share Option Options Exercise $0 -18,860 -47% $0.000000 21,552 09 Dec 2024 Class A Ordinary Share 18,860 $11.10 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.755. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023.
F5 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 8, 2022.